Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pacira BioSciences (PCRX)

Pacira Adds Samit Hirawat, M.D., to Board of Directors, Expanding It to 10 Members

Neutral Impact 2 of 5 leadership Written later

Pacira BioSciences appointed Dr. Samit Hirawat to its Board of Directors on January 27, 2026, effective immediately, as a Class III director. The Board increased its size from nine to 10 directors and named him to the Science and Technology Committee, and the company announced the appointment in a press release on January 28, 2026.

Key points

  • Board size increased from nine to 10 directors; Dr. Hirawat appointed as a Class III director effective immediately on January 27, 2026
  • Dr. Hirawat also appointed to the Board's Science and Technology Committee
  • Board determined Dr. Hirawat is independent under Nasdaq listing standards
  • Previously Chief Medical Officer and Head of Global Drug Development at Bristol Myers Squibb, and more than a decade at Novartis

The filing

CompanyPacira BioSciences (PCRX)
Form8-K, current report
Filed with the SECJan 28, 2026, 8:01 AM ET
Accession number0001628280-26-003717

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 28, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.